Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16333937rdf:typepubmed:Citationlld:pubmed
pubmed-article:16333937lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C0242618lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C0035608lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C0040223lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C1413520lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C1868673lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C0039789lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C0524527lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C0870078lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C1524031lld:lifeskim
pubmed-article:16333937lifeskim:mentionsumls-concept:C1514873lld:lifeskim
pubmed-article:16333937pubmed:issue11lld:pubmed
pubmed-article:16333937pubmed:dateCreated2005-12-7lld:pubmed
pubmed-article:16333937pubmed:abstractTextThe WHO- and IUATLD-recommended protocol for rifampicin (RMP) bioequivalence utilises 20-22 volunteers and 8 h, whereas the requirement of other regulatory authorities is 12 volunteers with a 24 h sampling schedule. Differing sampling size and time requirements may change the outcome of RMP bioequivalence.lld:pubmed
pubmed-article:16333937pubmed:languageenglld:pubmed
pubmed-article:16333937pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16333937pubmed:citationSubsetIMlld:pubmed
pubmed-article:16333937pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16333937pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16333937pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16333937pubmed:statusMEDLINElld:pubmed
pubmed-article:16333937pubmed:monthNovlld:pubmed
pubmed-article:16333937pubmed:issn1027-3719lld:pubmed
pubmed-article:16333937pubmed:authorpubmed-author:SinghIIlld:pubmed
pubmed-article:16333937pubmed:authorpubmed-author:KaulC LCLlld:pubmed
pubmed-article:16333937pubmed:authorpubmed-author:AgrawalSSlld:pubmed
pubmed-article:16333937pubmed:authorpubmed-author:KaurK JKJlld:pubmed
pubmed-article:16333937pubmed:authorpubmed-author:PanchagnulaRRlld:pubmed
pubmed-article:16333937pubmed:authorpubmed-author:BhadeSSlld:pubmed
pubmed-article:16333937pubmed:issnTypePrintlld:pubmed
pubmed-article:16333937pubmed:volume9lld:pubmed
pubmed-article:16333937pubmed:ownerNLMlld:pubmed
pubmed-article:16333937pubmed:authorsCompleteYlld:pubmed
pubmed-article:16333937pubmed:pagination1273-80lld:pubmed
pubmed-article:16333937pubmed:dateRevised2006-6-12lld:pubmed
pubmed-article:16333937pubmed:meshHeadingpubmed-meshheading:16333937...lld:pubmed
pubmed-article:16333937pubmed:meshHeadingpubmed-meshheading:16333937...lld:pubmed
pubmed-article:16333937pubmed:meshHeadingpubmed-meshheading:16333937...lld:pubmed
pubmed-article:16333937pubmed:meshHeadingpubmed-meshheading:16333937...lld:pubmed
pubmed-article:16333937pubmed:meshHeadingpubmed-meshheading:16333937...lld:pubmed
pubmed-article:16333937pubmed:meshHeadingpubmed-meshheading:16333937...lld:pubmed
pubmed-article:16333937pubmed:year2005lld:pubmed
pubmed-article:16333937pubmed:articleTitleMinimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations.lld:pubmed
pubmed-article:16333937pubmed:affiliationDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India.lld:pubmed
pubmed-article:16333937pubmed:publicationTypeJournal Articlelld:pubmed